Holen Sie sich die Stockscreener-App
44.28
0.63%
-0.28
Handel nachbörslich:
45.99
1.71
+3.86%
Schlusskurs vom Vortag:
$44.56
Offen:
$43.72
24-Stunden-Volumen:
2.40M
Relative Volume:
1.13
Marktkapitalisierung:
$8.44B
Einnahmen:
$2.69B
Nettoeinkommen (Verlust:
$-214.04M
KGV:
-37.85
EPS:
-1.17
Netto-Cashflow:
$98.43M
1W Leistung:
-1.58%
1M Leistung:
-6.88%
6M Leistung:
-33.32%
1J Leistung:
-39.19%
1-Tages-Spanne:
$43.27
$45.28
1-Wochen-Bereich:
$42.51
$45.28
52-Wochen-Spanne:
$40.62
$74.44
Exact Sciences Corp Stock (EXAS) Company Profile
Firmenname
Exact Sciences Corp
Sektor
Branche
Telefon
608-284-5700
Adresse
5505 ENDEAVOR LANE, MADISON, WI
Vergleichen Sie EXAS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EXAS
Exact Sciences Corp
|
44.28 | 8.44B | 2.69B | -214.04M | 98.43M | -1.17 |
|
TMO
Thermo Fisher Scientific Inc
|
470.03 | 177.32B | 42.88B | 6.34B | 7.27B | 16.53 |
|
DHR
Danaher Corp
|
197.90 | 141.59B | 23.88B | 3.90B | 5.30B | 5.28 |
|
IDXX
Idexx Laboratories Inc
|
410.76 | 33.29B | 3.90B | 887.87M | 798.08M | 10.67 |
|
A
Agilent Technologies Inc
|
109.67 | 31.28B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IQV
Iqvia Holdings Inc
|
167.69 | 29.57B | 15.41B | 1.37B | 2.11B | 7.50 |
Exact Sciences Corp Stock (EXAS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-13 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2025-01-23 | Eingeleitet | Barclays | Overweight |
| 2024-08-28 | Eingeleitet | Wells Fargo | Overweight |
| 2024-06-27 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-06-03 | Fortgesetzt | Jefferies | Buy |
| 2024-01-02 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2023-12-14 | Eingeleitet | Guggenheim | Buy |
| 2023-12-13 | Eingeleitet | Wolfe Research | Outperform |
| 2023-10-10 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2023-09-28 | Eingeleitet | Bernstein | Outperform |
| 2023-08-02 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2023-05-10 | Hochstufung | Craig Hallum | Hold → Buy |
| 2023-05-05 | Eingeleitet | UBS | Neutral |
| 2023-03-09 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-02-10 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2023-01-18 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2022-10-19 | Herabstufung | Craig Hallum | Buy → Hold |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-06-03 | Eingeleitet | Piper Sandler | Neutral |
| 2021-11-03 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2021-07-29 | Bestätigt | BTIG Research | Buy |
| 2021-07-29 | Bestätigt | Canaccord Genuity | Buy |
| 2021-07-29 | Bestätigt | Oppenheimer | Outperform |
| 2021-07-29 | Bestätigt | Stifel | Buy |
| 2021-06-15 | Eingeleitet | Raymond James | Strong Buy |
| 2021-06-03 | Eingeleitet | Goldman | Buy |
| 2021-05-25 | Eingeleitet | Wells Fargo | Equal Weight |
| 2021-01-28 | Eingeleitet | Truist | Buy |
| 2020-10-29 | Herabstufung | UBS | Buy → Neutral |
| 2020-10-28 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-10-08 | Fortgesetzt | BTIG Research | Buy |
| 2020-04-02 | Eingeleitet | Evercore ISI | Outperform |
| 2020-01-10 | Fortgesetzt | BTIG Research | Buy |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2019-12-13 | Eingeleitet | Dougherty & Company | Buy |
| 2019-11-15 | Eingeleitet | Stifel | Buy |
| 2019-10-17 | Bestätigt | BofA/Merrill | Buy |
| 2019-10-01 | Fortgesetzt | Craig Hallum | Buy |
| 2019-09-26 | Eingeleitet | Oppenheimer | Outperform |
| 2019-02-26 | Hochstufung | Goldman | Neutral → Buy |
| 2018-10-09 | Eingeleitet | UBS | Buy |
| 2018-09-05 | Fortgesetzt | The Benchmark Company | Hold |
| 2018-08-13 | Bestätigt | Canaccord Genuity | Buy |
| 2018-04-03 | Hochstufung | BTIG Research | Neutral → Buy |
| 2018-01-29 | Eingeleitet | Goldman | Neutral |
| 2018-01-08 | Bestätigt | The Benchmark Company | Buy |
| 2017-11-13 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2017-11-01 | Herabstufung | BTIG Research | Buy → Neutral |
Alle ansehen
Exact Sciences Corp Aktie (EXAS) Neueste Nachrichten
Exact Sciences Schedules First Quarter 2025 Earnings Call - The Joplin Globe
Cancer Screening Leader Exact Sciences Sets Q1 2025 Earnings Date: Key Details Inside - Stock Titan
Exact Sciences Launches the Cologuard Plus™ Test, Transforming Colorectal Cancer Screening - BioSpace
Revolutionary Cancer Test Achieves 95% Accuracy, Cuts Unnecessary Procedures by 40% - Stock Titan
Benchmark maintains Buy on Exact Sciences, price target at $65 By Investing.com - Investing.com South Africa
Benchmark maintains Buy on Exact Sciences, price target at $65 - Investing.com
Exact Sciences Positioned for Growth with Upcoming Product Launches and Margin Expansion - TipRanks
High Growth Tech Stocks To Watch In The US March 2025 - Yahoo Finance
Should You Retain Exact Sciences Stock in Your Portfolio Now? - Yahoo Finance
Why Exact Sciences Corporation (EXAS) is Among the Best Diagnostics Stocks to Invest in Right Now - Insider Monkey
12 Best Diagnostics Stocks to Invest In Right Now - Insider Monkey
Exact Sciences (EXAS) Down 10.6% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Should You Invest in Exact Sciences Corp. (EXAS)? - MSN
SERA PROGNOSTICS ANNOUNCES APPOINTMENT OF JEFF ELLIOTT TO ITS BOARD; RYAN TRIMBLE AND MARCUS WILSON TO STEP DOWN - Quantisnow
Former Exact Sciences COO Joins Sera Prognostics Board Amid Strategic Expansion - Stock Titan
"Pick Up Your Poop" F Cancer's New Campaign Encourages At-Home Colorectal Cancer Screening - WV News
RBC Capital Initiates Coverage of Exact Sciences (BMV:EXAS) with Sector Perform Recommendation - Nasdaq
Commit To Buy EXACT Sciences At $30, Earn 14% Using Options - Nasdaq
Expert Outlook: Exact Sciences Through The Eyes Of 7 Analysts - Benzinga
PreventionGenetics Assumes the Management of Sponsored Genetic Testing Program for Three Rare Genetic Diseases: Acute Hepatic Porphyria, Primary Hyperoxaluria Type 1 & Hereditary ATTR Amyloidosis - Business Wire
Exact Sciences initiated with a Sector Perform at RBC Capital - TipRanks
Exact Sciences Named 2025 Gallup Exceptional Workplace Award Winner - Joplin Globe
Exact Sciences Triples Industry Average in Employee Engagement, Wins Prestigious Gallup Award - StockTitan
New Data Highlight the Positive Impact of Exact Sciences’ Oncotype DX - Business Wire
Charles Schwab Investment Management Inc. Grows Holdings in Exact Sciences Co. (NASDAQ:EXAS) - Defense World
Exact Sciences Co. (NASDAQ:EXAS) Stake Increased by Jones Financial Companies Lllp - Defense World
3 Top Cancer Biotechs to Keep An Eye On in 2025 - Yahoo Finance
Exact Sciences at Raymond James Conference: Strategic Growth and Innovation - Investing.com
Cancer Biomarkers Research Report 2024: Global Market Projected to Soar to USD 62.14 Billion by 2034, Driven by Technological Advancements and Increasing Demand for Early Detection - GlobeNewswire Inc.
La Paloma CC: Set to host PGA Tour Champions' Cologuard Classic - The First Call
Here’s What Led Artisan Mid Cap Fund to Trim Exact Sciences Corporation (EXAS) - Yahoo Finance
Exact Sciences Corporation (EXAS): Among the Cash-Rich Mid Cap Stocks to Buy Now - Insider Monkey
Truist Financial Corp Sells 1,905 Shares of Exact Sciences Co. (NASDAQ:EXAS) - Defense World
Exact Sciences Co. (NASDAQ:EXAS) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
EXACT Sciences Corp. to Host Earnings Call - ACCESS Newswire
Exact Sciences Co. (NASDAQ:EXAS) Shares Sold by New York State Common Retirement Fund - MarketBeat
Atria Wealth Solutions Inc. Takes $316,000 Position in Exact Sciences Co. (NASDAQ:EXAS) - Defense World
Heritage Investors Management Corp Has $4.29 Million Stake in Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat
Generali Investments Towarzystwo Funduszy Inwestycyjnych Acquires 6,000 Shares of Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat
Exact Sciences Co. (NASDAQ:EXAS) Shares Acquired by Sanctuary Advisors LLC - Defense World
Exact Sciences (NASDAQ:EXAS) Price Target Cut to $70.00 by Analysts at Piper Sandler - MarketBeat
Exact Sciences (NASDAQ:EXAS) Shares Up 4.8% After Analyst Upgrade - MarketBeat
2 Stocks Down 59% and 34% to Buy and Hold - The Globe and Mail
Exact Sciences to Participate in March Investor Conferences - BioSpace
Exact Sciences price target raised to $73 from $70 at Scotiabank - TipRanks
Healthcare Spotlight: Exact Sciences Takes Center Stage at Two Major March Conferences - StockTitan
symbol__ Stock Quote Price and Forecast - CNN
Exact Sciences Stock Climbs After Strong Q2 Results - MSN
Bank of America Has Lowered Expectations for Exact Sciences (NASDAQ:EXAS) Stock Price - Defense World
Exact Sciences Reports Strong Revenue Growth in 2024 - TipRanks
What's Going On With Cancer Diagnostic Firm Guardant Health On Friday? - Benzinga
Finanzdaten der Exact Sciences Corp-Aktie (EXAS)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.14%
1.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):